Burcon NutraScience Corp.

  • WKN: 157793
  • ISIN: CA1208311029
  • Land: Kanada

Nachricht vom 19.09.2019 | 11:33

Burcon NutraScience Corp.: Burcon Announces Results of Shareholder Meeting

DGAP-News: Burcon NutraScience Corp. / Key word(s): AGM/EGM

19.09.2019 / 11:33
The issuer is solely responsible for the content of this announcement.


Burcon Announces Results of Shareholder Meeting

Vancouver, British Columbia, September 18, 2019 - Burcon NutraScience Corporation (TSX: BU) a global technology leader in the development of plant-based proteins, is pleased to announce the results from its 2019 annual meeting of shareholders (the "Meeting") held on September 17, 2019.  All of the seven nominees set out in Burcon's management proxy circular dated July 30, 2019 proposed by management for election to the board of directors at the Meeting were elected to the board.  Each director elected will hold office until the conclusion of the next annual meeting of shareholders of Burcon or until his or her successor is elected or appointed, unless his or her office is earlier vacated in accordance with Burcon's by-laws or with the provisions of the Business Corporations Act (Yukon).

The results of the voting on the election of the directors are as follows:
 
Director Nominee Votes For % Votes For Votes Withheld % Votes Withheld Non Votes
Rosanna Chau 31,279,384 97.79 708,150 2.21 2,034,011
David Lorne John Tyrrell 31,761,189 99.29 226,345 0.71 2,034,011
Alan Chan 31,759,239 99.29 228,295 0.71 2,034,011
J. Douglas Gilpin 31,760,239 99.29 227,295 0.71 2,034,011
Peter H. Kappel 31,760,239 99.29 227,295 0.71 2,034,011
David Ju 31,351,164 98.01 636,370 1.99 2,034,011
Calvin Chi Leung Ng 31,372,304 98.08 615,230 1.92 2,034,011


Shareholders of the Corporation also approved all other items of business brought forward at the Meeting.

About Burcon NutraScience Corporation
Burcon is a global technology leader in the development of plant-based proteins.  The company has developed an extensive portfolio of composition, application, and process patents originating from a core protein extraction and purification technology.  Burcon's family of plant proteins includes Peazazz(R),  a uniquely soluble and clean-tasting pea protein, Puratein(R), Supertein(R) and Nutratein(R) canola proteins with exceptional functionality and valuable nutritional profiles, and Nutratein-PS(TM) and Nutratein-TZ(TM), Burcon's new pea and canola protein blends that have exceptional functional characteristics, low allergenicity, and a nutritional value exceeding those of standard pea proteins in the market today.  Burcon's CLARISOY(R) soy protein - under license to the Archer Daniels Midland Company - offers clarity and high-quality protein nutrition for low-pH beverage systems, and excellent solubility and exceptionally clean flavour at any pH. For more information about the company, visit www.burcon.ca.


The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated July 2, 2019 filed with the Canadian securities administrators on www.sedar.com.  Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact:
Paul Lam
Manager, Business Development
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca  www.burcon.ca

Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM

 


19.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“

- Emissionsvolumen: bis zu 60 Mio. Euro
- ISIN: DE000A2YPAJ3 / WKN: A2YPAJ
- Stückelung / Mindestanlage: 1.000 Euro - Zinssatz (Kupon): Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG beauftragt unabhängige Prüfung

21. Oktober 2019, 07:40

Aktuelle Research-Studie

CO.DON AG

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

21. Oktober 2019